NGNE · Neurogene Inc. · Financials
Market Cap
$710.00M
Shares
20.01M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
-100%
FY2025
Net Income
-$90.35M
-20.2%
FY2025
Operating Margin
-8930.27%
FY2024
Diluted EPS
-$4.24
+0.9%
FY2025
Operating Cash Flow
-$77.17M
-9.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $925K | $0 | — | — | — | — | $25M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.79M | — | — | — | $1.58M | $19K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $88.5M | $75.01M | $60.92M | $44.39M | $47.51M | $39.16M | $24.34M | $4.42M | $41.79M | $36.27M | $28.38M | $15.8M | $18.08M | $7.6M | $6.05M | — | — | — | — | — | — | — | — | |
| $32.84M | $28.32M | $22.61M | $11.19M | $9.01M | $21.54M | $17.21M | $18.83M | $15.84M | $14.85M | $9.26M | $5.54M | $4.3M | $1.78M | $1.64M | — | — | — | — | — | — | — | — | |
| — | — | — | — | $100K | $200K | $200K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.15M | $3.04M | $3.2M | $3.26M | $3.2M | $1.31M | $785K | $340K | $289K | $360K | — | — | $135.95K | $59.57K | $130.78K | — | — | — | — | — | — | — | — | |
| — | — | — | — | $1.41M | — | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $121.35M | $103.33M | $83.53M | $55.58M | $56.52M | $60.7M | — | $70.96M | $57.62M | $51.12M | $37.65M | $21.34M | $22.38M | $9.38M | $7.68M | — | — | — | — | — | — | — | — | |
| -$121.35M | -$103.33M | -$82.61M | -$55.58M | -$56.52M | -$60.7M | -$33.73M | -$70.96M | -$32.62M | -$51.12M | -$37.65M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -8930.27% | — | — | — | — | — | -130.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$118.19M | -$100.29M | -$79.41M | -$52.32M | -$53.32M | -$59.39M | -$32.94M | -$70.62M | -$32.34M | -$50.76M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $2000 | $5000 | $12K | $12K | $2000 | — | — | $1000 | $4000 | $4000 | $1000 | — | $451K | $42.92K | $9470 | — | — | — | — | — | — | — | — | |
| $9.72M | $11.55M | $8.47M | $2.95M | $1.34M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $12.98M | $7.46M | — | -$42K | -$13K | $451K | $1.52M | $1.04M | $936K | $643K | -$520K | -$1.65M | $642K | $9114 | — | — | — | — | — | — | — | — | |
| — | -$90.35M | -$75.14M | -$36.32M | -$55.19M | -$60.69M | -$33.28M | -$69.44M | -$31.59M | -$50.18M | -$37M | -$21.86M | -$24.03M | -$8.73M | -$7.67M | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | — | — | — | — | — | — | — | $0 | $0 | $0 | -$5000 | $42.29K | — | — | — | — | — | — | — | — | |
| -$111.11M | -$90.35M | -$75.14M | -$36.32M | -$55.19M | -$60.69M | -$33.28M | -$69.44M | -$31.59M | -$50.18M | -$37M | -$21.86M | -$24.03M | -$8.73M | -$7.71M | — | — | — | — | — | — | — | — | |
| — | — | -8123.68% | — | — | — | — | — | -126.34% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$37M | -$21.86M | -$23.82M | -$14.94M | -$12.14M | — | — | — | — | — | — | — | — | |
| -$34.17M | — | — | — | -$57.58M | -$60.69M | — | -$69.44M | -$31.52M | -$50.08M | -$36.88M | -$22.15M | -$24.03M | -$8.73M | -$7.71M | -$10.51M | -$8.53M | -$3.75M | -$5.46M | -$2.01M | -$543.05K | -$19.28K | -$12.19K | |
| USD/shares | -$5.03 | -$4.24 | -$4.28 | — | -$20.80 | -$22.00 | -$12.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$5.03 | -$4.24 | -$4.28 | — | -$20.80 | -$22.00 | -$12.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 21.33M | 17.57M | — | 2.76M | 2.75M | 2.59M | 1.35M | 1.18M | 1.17M | 944.68K | 631.89K | 433.37K | 15.09K | 15.09K | — | — | — | — | — | — | — | — |
| shares | — | 21.33M | 17.57M | — | 2.76M | 2.75M | 2.59M | 1.35M | 1.18M | 1.17M | 944.68K | 631.89K | 433.37K | 15.09K | 15.09K | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.54×
EV/EBIT
—
Peer median 10.93×
P/E (TTM)
—
Peer median 13.19×
Peer medians compare against the 306 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 |
|---|---|---|
| Reportable Segment | $925,000 | $0 |
Key facts
CIK
1404644
CUSIP
64135M105
13F (30d)
44 filings
44 filers
Visit website
Investor relations